



## Introducing KOVALTRY™

– a new Factor VIII treatment for hemophilia A from the makers of KOGENATE® FS

Dear Healthcare Provider,

March 2016

Bayer is pleased to announce our latest product offering – Kovaltry™. Kovaltry™ will be available starting in June 2016 and thereafter Kogenate® FS will gradually be phased out across Canada.

Kovaltry™ is indicated in the treatment of **hemophilia A** in adults and children.<sup>1</sup>

Kovaltry™ (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for:<sup>1</sup>

- Routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes
- Control and prevention of episodic bleeding
- Peri-operative management (surgical prophylaxis)

Kovaltry™ does not contain von Willebrand factor and is not indicated for the treatment of von Willebrand disease.<sup>1</sup>

Kogenate® FS (Antihemophilic Factor [Recombinant]) is indicated:<sup>2</sup>

- for the treatment of classical hemophilia (hemophilia A), in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor VIII (FVIII). Kogenate® FS provides a means of temporarily replacing the missing clotting factor in order to correct or prevent bleeding episodes, or in order to perform emergency or elective surgery in patients with hemophilia
- to prevent the occurrence of spontaneous hemorrhagic episodes and to prevent joint damage in children with no pre-existing joint damage, when used as a regular prophylactic treatment
- to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A, when used as a regular prophylactic treatment

For more information, please consult the Kovaltry™ Product Monograph at [www.bayer.ca/kovaltry-pm-en](http://www.bayer.ca/kovaltry-pm-en).



### Look for product availability starting June 2016

Kovaltry™ is available in 250, 500, 1,000, 2,000 and 3,000 IU vials and is supplied with a Vial Adapter<sup>\*</sup>

Please consult the Kovaltry™ and Kogenate® FS Product Monographs at [www.bayer.ca/kovaltry-pm-en](http://www.bayer.ca/kovaltry-pm-en) and <http://omr.bayer.ca/omr/online/kogenate-fs-pm-en-vial-adapter.pdf>, respectively, for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monographs are also available by calling 1-800-265-7382.

**Interested in learning more?** Please contact your local Business Relations Manager or Bayer Medical Information at 1-800-265-7382 (7:30 am to 7:30 pm EST) for more information.

Best regards,

Rena Battistella  
Business Unit Head, Hematology  
Bayer HealthCare

\* Canadian packaging may appear different.

References: 1. Kovaltry™ Product Monograph, Bayer Inc., January 27, 2016.  
2. Kogenate® FS Product Monograph, Bayer Inc., November 21, 2015.

Bayer Inc., 2920 Matheson Blvd. E., Mississauga, Ontario L4W 5R6  
© TM see [www.bayer.ca/tm-mc](http://www.bayer.ca/tm-mc)  
© 2016, Bayer Inc.



KVL101-0216B L.CA.MKT.01.2016.1311



Antihemophilic Factor (Recombinant)